Flagship Takes a Stab at Microbiome Therapy With Seres Health
Summary
Flagship Takes a Stab at Microbiome Therapy With Seres Health Xconomy Boston — We live every day with trillions of bacterial neighbors that do all sorts of mysterious things in our guts, good and bad.The latest company to emerge from Flagship VentureLabs, Seres Health, is coming out of stealth mode (at least partially) after a little more than two years of toiling behind closed doors.Unlike most biotech startups seeking their first bit of public attention, Seres has advanced all the way to its first clinical trial, and dosed its first patient, with an internally developed treatment.The goal at Seres, Berry says, is to essentially tread more lightly with drugs that alter what he calls the “functional ecology” of a diseased person’s microbiome, and tip it back into a healthy state.When I asked him how these products are manufactured consistently up to FDA standards—a really important thing—he declined to go into detail other than to say, “We’ve spent quite a bit of time figuring this out.
Classifications
AskAI Classifications
LabelsLinked Companies
